These results highlight the need to further develop a safe and reliable WNT5A inhibitor to be used in combination with a Rho GTPase inhibitor as a clinical treatment strategy to effectively impair melanoma cell invasion and metastasis. This evidence concerns the gene WNT5A and melanoma.